Stocks and Investing
Stocks and Investing
Thu, February 25, 2016
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Wed, February 24, 2016
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Tue, February 23, 2016
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Andrew Baum Upgraded (ABBV) to Strong Buy and Increased Target to $65 on, Feb 23rd, 2016
Andrew Baum of Citigroup, Upgraded "AbbVie Inc." (ABBV) to Strong Buy and Increased Target from $56 to $65 on, Feb 23rd, 2016.
Andrew has made no other calls on ABBV in the last 4 months.
There are 2 other peers that have a rating on ABBV. Out of the 2 peers that are also analyzing ABBV, 1 agrees with Andrew's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Steve Chesney of "Atlantic Equities" Initiated at Hold and Held Target at $59 on, Friday, December 18th, 2015
This is the rating of the analyst that currently disagrees with Andrew
- Jeffrey Holford of "Jefferies" Maintained at Strong Buy with Decreased Target to $80 on, Thursday, January 14th, 2016
Contributing Sources